VPRIV is administered intravenously, with the initial dosage depending on whether the patient is naive to therapy or switching from another enzyme replacement therapy.

Dosage and Administration of VPRIV

VPRIV should be administered as an intravenous infusion under the supervision of healthcare professionals. The recommended starting dose for patients naïve to enzyme replacement therapy is 60 Units/kg every two weeks. For patients switching from imiglucerase to VPRIV, treatment can begin with the previous imiglucerase dose, two weeks after the last imiglucerase infusion. VPRIV comes as a lyophilized powder that must be reconstituted with sterile water, and the final solution should be diluted before administration. It is important to monitor for hypersensitivity reactions, and administration should include appropriate medical support measures, including access to resuscitation equipment.